Your gut microbiome contains a large community of microbes, including bacteria, archaea, protists, fungi and viruses. Most live in your digestive tract, affecting everything from your immune system to your metabolism.
We are pioneering microbiome science rooted in the gastrointestinal (GI) tract to advance innovative therapeutics designed to protect and preserve your health. Our team is comprised of industry leaders and veterans with wide-ranging scientific and manufacturing roots who are keenly focused on developing and advancing ground breaking microbiome research in support of our novel pipeline of GI-focused therapeutics.
Learn more about our scienceOur two lead candidates include:
| Candidate & Indication | Development Stage | ||||
|---|---|---|---|---|---|
| Preclinical | Phase 1 | Phase 2 | Phase 3 | Market | |
| SYN-004 (ribaxamase) Prevention of CDI, pathogenic overgrowth, AMR and aGVHD in allogeneic HCT recipients | |||||
| SYN-004 (ribaxamase) Prevention of CDI, pathogenic overgrowth, AMR and aGVHD in allogeneic HCT recipients |
Preclinical Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase complete
|
Phase 3 Phase not started
|
Market Phase not started
|
| SYN-020 Celiac disease, NAFLD, radiation enteritis, and age-related metabolic and inflammatory diseases | |||||
| SYN-020 Celiac disease, NAFLD, radiation enteritis, and age-related metabolic and inflammatory diseases |
Preclinical Phase complete
|
Phase 1 Phase in progress
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
Market Phase not started
|
Our innovative GI-focused development pipeline is designed to address large unmet medical needs and safeguard patient wellness.
Fill out the form below for more information.
Join the conversation.
Contact UsStay current with news and announcements.
SIGN UP FOR UPDATES